VIA
IMDZ

Vident Investment Advisory’s Immune Design Corp. IMDZ Stock Holding History

Vident Investment Advisory’s Portfolio IMDZ Stock Details IMDZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-73,608
Closed -$956 – 406
2016
Q1 		$956 Buy
73,608
+35,224
+92% +$407K 0.06% 352
2015
Q4 		$771K Buy
+38,384
New +$661K 0.1% 338

Other funds holding IMDZ

PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vident Investment Advisory's IMDZ Position: Q2 2016 in Review

Vident Investment Advisory sold out of Immune Design Corp. (IMDZ) in Q2 2016, closing a stake of 73,608 shares — an estimated $956 sold.

Vident Investment Advisory first reported a position in IMDZ in Q4 2015 and held it in 2 quarters. The position peaked at $771K in Q4 2015. 60 funds tracked by Wall St. Rank hold IMDZ as of Q2 2016.

  • Vident Investment Advisory reported no remaining Immune Design Corp. position as of Q2 2016 after selling out during the quarter.
  • Vident Investment Advisory sold 73,608 Immune Design Corp. shares in Q2 2016, an estimated $956.
  • Vident Investment Advisory first reported a position in Immune Design Corp. in Q4 2015 and held it in 2 quarters.
  • Vident Investment Advisory's Immune Design Corp. position peaked at $771K in Q4 2015.
  • 60 funds tracked by Wall St. Rank held Immune Design Corp. as of Q2 2016.

Based on Vident Investment Advisory's 13F filing for Q2 2016, filed 12 Aug 2016.